论文部分内容阅读
自从1980年开发诺氟沙星以来,已开发出许多临床应用的氟取代吡啶酮酸类抗菌剂,到目前为至已有近十个氟喹诺酮类药物上市供医用,而且还有一系列的氟喹诺酮类药物正在临床评价中。 AM—1091(Bay-V-3545,CI-960,PD-127391)是日本杏林公司最近开发的对革兰氏阳性菌,革兰氏阴性菌和厌氧菌均有很强活性的新一代超广谱喹诺酮类抗菌剂,目前正处于Ⅱ期临床阶段。化学名称:7-(3-氨基-1-吡咯烷基)-8-氯-1-环丙基-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸盐酸盐。结构式:
Since the development of norfloxacin in 1980, a number of clinical applications have been developed for fluoro-substituted pyridone acid antibacterials, up to now there are nearly 10 fluoroquinolones listed for medical use, but also a series of fluoroquinolones Drugs are in clinical evaluation. AM-1091 (Bay-V-3545, CI-960, PD-127391) is a new generation developed by Japan’s Kyorin Co., Ltd., which is highly active against gram positive bacteria, gram negative bacteria and anaerobic bacteria Broad-spectrum quinolone antibacterial agents, is currently in Phase II clinical stage. Chemical Name: 7- (3-Amino-1-pyrrolidinyl) -8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylate Acid salt. Structure: